Efficacy News and Research

RSS

Isis Pharmaceuticals receives $2.15 million milestone payment to advance ISIS-SMN Rx study in children with SMA

Isis Pharmaceuticals, Inc. announced today that it has earned a $2.15 million milestone payment from Biogen related to advancing the ongoing pivotal Phase 3 study (CHERISH) evaluating ISIS-SMN Rx in children with spinal muscular atrophy (SMA).

14 Jul 2015

Ferrer begins Lorediplon phase IIa trial in patients with insomnia disorder

Ferrer, a privately-held Spanish pharmaceutical company, today announces the first patient has been recruited into a phase IIa clinical trial to test the efficacy, safety and tolerability profile of Lorediplon in adult patients with insomnia disorder. The study is scheduled to be completed by Q4, 2016.

14 Jul 2015

New analysis explores importance of medical imaging in drug development, understanding pathological physiology

The use of small animal models in basic and preclinical research is now an integral part of developing and testing new pharmaceutical drugs prior to commercialisation.

14 Jul 2015

Cognitive behavioral therapy effective for insomnia with psychiatric and medical conditions

Cognitive behavioral therapy is a widely used nonpharmacologic treatment for insomnia disorders and an analysis of the medical literature by sleep researchers at Rush University Medical Center suggests it also can work for patients whose insomnia is coupled with psychiatric and medical conditions, according to an article published online by JAMA Internal Medicine.

14 Jul 2015

Biosimilars show promise for children with IBD, but more research needed

Children with inflammatory bowel disease (IBD) who are doing well on specific biological medications should not be switched to recently approved "biosimilar" products, concludes an expert consensus statement of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition.

14 Jul 2015

Study shows that Anisina has potential to improve effectiveness of chemotherapy in children with cancer

US-Australian drug discovery company, Novogen Limited, today announced details of an in vivo proof of concept study that demonstrates their lead anti-tropomyosin drug candidate, Anisina, has the potential to improve the effectiveness of chemotherapy in children and reduce life-long side-effects.

14 Jul 2015

FDA accepts Blueprint Medicines' IND applications to start Phase 1 clinical trials for two drug candidates

Blueprint Medicines today announced that the U.S. Food and Drug Administration accepted the Company's Investigational New Drug (IND) applications to begin Phase 1 clinical trials for its two lead drug candidates: BLU-554 for the treatment of advanced hepatocellular carcinoma (HCC) and cholangiocarcinoma, and BLU-285 for unresectable, treatment-resistant gastrointestinal stromal tumor (GIST).

13 Jul 2015

Lixiana (edoxaban) recommended for treating, preventing recurrent DVT and PE in adults

The National Institute for Health and Care Excellence has recommended a new treatment to help patients suffering from blood clots in the legs and lungs.

13 Jul 2015

Diabetes drug metformin does not stop babies from being born overweight

Treating obese pregnant women with a diabetes drug does not stop their babies from being born overweight, a study has found.

12 Jul 2015

IMBRUVICA (ibrutinib) approved in Europe for treatment of Waldenstrom's macroglobulinemia

Today AbbVie announced the European Commission granted marketing authorization for IMBRUVICA (ibrutinib) as the first treatment option available in all 28 member states of the European Union for the treatment of Waldenstrom's macroglobulinemia (WM), a rare, slow growing blood cancer, in adult patients who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy.

12 Jul 2015

Anika Therapeutics announces positive results from CINGAL phase 3 trial for knee osteoarthritis

Anika Therapeutics, Inc.,, a leader in products for tissue protection, healing, and repair based on hyaluronic acid technology, today reported positive results from the CINGAL 13-02 study evaluating the safety of a repeat injection of Cingal for symptomatic relief of osteoarthritis of the knee.

10 Jul 2015

UTHealth scientist receives $1.9 million from NIH to develop non-antibiotic treatment for C. diff infections

Charles Darkoh, Ph.D., a researcher at The University of Texas Health Science Center at Houston School of Public Health, was recently awarded a five-year, $1.9 million R01 grant by the National Institutes of Health to develop a non-antibiotic treatment for Clostridium difficile (C. diff) infections.

10 Jul 2015

Janssen-sponsored Phase 2b trial shows guselkumab effective in treating moderate to severe plaque psoriasis

Results published today in The New England Journal of Medicine from a Janssen Research & Development, LLC (Janssen)-sponsored Phase 2b trial showed up to 86 percent of patients with moderate to severe plaque psoriasis receiving guselkumab (CNTO 1959) achieved a Physician's Global Assessment (PGA) score of cleared psoriasis or minimal psoriasis at week 16, the study's primary endpoint.

9 Jul 2015

Up-to-date treatment and diagnostic guidelines for diabetic retinal degeneration

Around 600,000 Austrians suffer from diabetes. This condition is frequently associated with serious retinal disorders. Along with age-related macular degeneration, diabetic retinal degeneration is one of the most common causes of blindness. The Department of Ophthalmology and Optometry at MedUni Vienna was chosen by the European Society of Retina Specialists (EURETINA) to coordinate the development of up-to-date treatment and diagnostic guidelines.

9 Jul 2015

Study analyzes attitudes and practices of general physicians in different vaccination scenarios

At population level, vaccines contribute to reducing mortality associated with infectious diseases such as measles, diphtheria, tetanus, hepatitis B or bacterial meningitis.

9 Jul 2015

Researchers discover molecule that may favour production of induced pluripotent cells

Since 2006, research has succeeded in generating, from specialised adult cells, induced pluripotent cells (iPS cells), with huge potential applications, particularly for regenerative medicine. However, the process has still not been completely mastered. Two teams of researchers from Inserm, CNRS, Centre Léon Bérard and Claude Bernard Lyon 1 University have discovered a molecule that may favour the production of these induced stem cells.

9 Jul 2015

Phase 3 ODYSSEY JAPAN trial of Praluent injection meets primary endpoint

Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the Phase 3 ODYSSEY JAPAN trial of the investigational therapy Praluent® (alirocumab) Injection met its primary endpoint.

9 Jul 2015

Study: Brain activity changes after memory retraining in TBI patients

Kessler Foundation researchers published results of their TBI-MEM trial, the first study to demonstrate significant changes in cerebral activation after memory retraining in individuals with traumatic brain injury.

9 Jul 2015

Guselkumab drug more effective than current standard of care for psoriasis

A phase II clinical trial led by Northwestern Medicine investigators shows that a new psoriasis drug called guselkumab has greater efficacy than the current standard of care for the chronic skin condition.

9 Jul 2015

Partnerships between healthcare insurers and pharmaceutical companies promote real-world value

PwC's Health Research Institute (HRI) reports that market forces are driving new sector collaborations– pairing traditional drug makers with insurers, health systems, patient groups and technology firms – to maximize real-world value and health outcomes.

9 Jul 2015

Efficacy News and Research

Isis Pharmaceuticals receives $2.15 million milestone payment to advance ISIS-SMN Rx study in children with SMA

Ferrer begins Lorediplon phase IIa trial in patients with insomnia disorder

New analysis explores importance of medical imaging in drug development, understanding pathological physiology

Cognitive behavioral therapy effective for insomnia with psychiatric and medical conditions

Biosimilars show promise for children with IBD, but more research needed

Study shows that Anisina has potential to improve effectiveness of chemotherapy in children with cancer

FDA accepts Blueprint Medicines' IND applications to start Phase 1 clinical trials for two drug candidates

Lixiana (edoxaban) recommended for treating, preventing recurrent DVT and PE in adults

Diabetes drug metformin does not stop babies from being born overweight

IMBRUVICA (ibrutinib) approved in Europe for treatment of Waldenstrom's macroglobulinemia

Anika Therapeutics announces positive results from CINGAL phase 3 trial for knee osteoarthritis

UTHealth scientist receives $1.9 million from NIH to develop non-antibiotic treatment for C. diff infections

Janssen-sponsored Phase 2b trial shows guselkumab effective in treating moderate to severe plaque psoriasis

Up-to-date treatment and diagnostic guidelines for diabetic retinal degeneration

Study analyzes attitudes and practices of general physicians in different vaccination scenarios

Researchers discover molecule that may favour production of induced pluripotent cells

Phase 3 ODYSSEY JAPAN trial of Praluent injection meets primary endpoint

Study: Brain activity changes after memory retraining in TBI patients

Guselkumab drug more effective than current standard of care for psoriasis

Partnerships between healthcare insurers and pharmaceutical companies promote real-world value

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News